A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC

por Lai, Gillianne G.Y., Yeo, Jia Chi, Jain, Amit, Zhou, Siqin, Pang, Mengyuan, Alvarez, Jacob J.S., Sim, Ngak Leng, Tan, Aaron C., Suteja, Lisda, Lim, Tze Wei, Guo, Yu Amanda, Shen, Meixin, Saw, Stephanie P.L., Rohatgi, Neha, Yeong, Joe P.S., Takano, Angela, Lim, Kiat Hon, Gogna, Apoorva, Too, Chow Wei, Da Zhuang, Kun, Tan, Wan Ling, Kanesvaran, Ravindran, Ng, Quan Sing, Ang, Mei Kim, Rajasekaran, Tanujaa, Wang, Lanying, Toh, Chee Keong, Lim, Wan-Teck, Tam, Wai Leong, Tan, Sze Huey, Skanderup, Anders M.J., Tan, Eng-Huat, Tan, Daniel S.W.
Publicado 2022